Krebs Biochemicals and Industries Limited has informed the Exchange about Copy of Newspaper Publication
KREBSBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Krebs Biochemicals and Industries Limited has submitted copies of newspaper publication of its unaudited financial results for the quarter ended June 30, 2025 (Q1 FY26). The results were published in Business Standard (English) and Prajasakti (Telugu) on August 8, 2025, after board approval on August 7. Total income from operations stood at Rs. 549.26 lakhs, down from Rs. 643.85 lakhs in the same quarter last year. The company reported a net loss of Rs. 532.43 lakhs for the quarter, narrower than the Rs. 826.84 lakhs loss posted in Q1 FY25. Basic and diluted loss per share was Rs. 2.47, compared to Rs. 3.83 in the year-ago period. Equity share capital remained unchanged at Rs. 2,156.06 lakhs.
The company continues to report quarterly losses, which may keep sentiment weak. However, the year-on-year narrowing of losses and reduced loss per share are modest positives, though the falling top line remains a concern for shareholders.